You've got the basics right. Here's the detailed picture for 2026:
Traditional Medicare Part D:
- Covers GLP-1s for diabetes indication ONLY (Ozempic, Mounjaro, Trulicity)
- The $2,000 annual OOP cap is in effect — once you hit that, you pay $0 for the rest of the year
- With the OOP cap, even expensive drugs like Ozempic become effectively cheaper in the back half of the year
- Weight-loss-only GLP-1s (Wegovy, Zepbound) remain excluded from Part D by statute — Medicare literally cannot cover them for obesity alone
Medicare Advantage (Part C):
- Some MA plans have started offering supplemental benefits that include weight management drugs
- Humana and UHC Medicare Advantage have specific plans in certain markets with limited GLP-1 coverage for weight loss
- This varies wildly by geography — check your specific plan
The Treat and Reduce Obesity Act has been introduced multiple times but as of early 2026 has not passed. If it does, it would allow Medicare Part D to cover FDA-approved anti-obesity medications. But don't hold your breath.